Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Explore this paper's citation graph
Summary
An RNA-interference-based genetic screen in human cells is performed to search for kinases whose knockdown synergizes with BRAF(V600E) inhibition, and it is reported that blockade of the epidermal growth factor receptor (EGFR) shows strong synergy with BRAFs inhibition.
- Type
- article
- Published
- 2012-01-26
- Cited by
- 1,949
- References
- 26
- Access
- Open access
- OpenAlex
- https://openalex.org/W2014881369
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:4330149
Keywords
Vemurafenib, V600E, Cancer research, Melanoma, Cetuximab
References
- Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
- High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.
- Identification of Epidermal Growth Factor Receptor as a Target of Cdc25A Protein Phosphatase*
- Transient Poly(ADP-ribosyl)ation of Nuclear Proteins and Role of Poly(ADP-ribose) Polymerase in the Early Stages of Apoptosis*
- The Concept of Synthetic Lethality in the Context of Anticancer Therapy
- The Protein Kinase Complement of the Human Genome
- BRAF mutations are associated with some histological types of papillary thyroid carcinoma
- Epidermal growth factor-related peptides and their receptors in human malignancies.
- ZNF423 Is Critically Required for Retinoic Acid-Induced Differentiation and Is a Marker of Neuroblastoma Outcome
- Regulation of Cdc25C by ERK-MAP kinases during the G2/M transition.
- BRAF MUTATIONS IN HAIRY CELL LEUKEMIA
- BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas.
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
- KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.
- EGFR in melanoma: clinical significance and potential therapeutic target
- Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.
- K-ras mutations and benefit from cetuximab in advanced colorectal cancer.
- Mutations of the BRAF gene in human cancer
- An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors
Cited by
- Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer
- Markers of resistance to anti-EGFR therapy in colorectal cancer.
- Detecting mechanisms of acquired BRAF inhibitor resistance in melanoma.
- A Systems Biology Approach to Personalizing Therapeutic Combinations
- A framework for genomic biomarker actionability and its use in clinical decision making
- Biomarkers for personalized medicine in GI cancers.
- New therapeutic strategies for BRAF mutant colorectal cancers.
- Clinical efficacy and drug resistance of anti-epidermal growth factor receptor therapy in colorectal cancer.
- New Therapeutic Opportunities Based on DNA Mismatch Repair and BRAF Status in Metastatic Colorectal Cancer
- Inhibition of BRAF kinase suppresses cellular proliferation, but not enough for complete growth arrest in BRAF V600E mutated papillary and undifferentiated thyroid carcinomas
- Findings made in gene panel to whole genome sequencing: data, knowledge, ethics – and consequences?
- Inhibition of RAF1 kinase activity restores apicobasal polarity and impairs tumour growth in human colorectal cancer
- Emerging treatment options for BRAF-mutant colorectal cancer
- Current Opportunities and Future Vision of Precision Medicine in Radiation Oncology
- Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations
- The Clinical Landscape of Circulating Tumor DNA in Gastrointestinal Malignancies
- Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study
- Identifying chemogenetic interactions from CRISPR screens with drugZ
- Novel antineoplastics targeting genetic changes in colorectal cancer.
- Clinical biomarkers in colorectal cancer.
Related papers
- Comparison of the therapeutic outcome between gefitinib and erlotinib in female patients with non-small-cell lung cancer
- Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer.
- Successful treatment of non-small cell lung cancer with gefitinib after severe erlotinib-related hepatotoxicity.
- Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure of gefitinib treatment
- Erlotinib is a well-tolerated alternate treatment for non-small cell lung cancer in cases of gefitinib-induced hepatotoxicity.
- [Gefitinib versus Erlotinib as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer].
- Comparison of the efficacy of gefitinib and erlotinib as a second line treatment for advanced non-small cell lung cancer
- Long-term survival of non-small-cell lung cancer patients with EGFR inhibitor treatment.
- Sequential responses of adenocarcinoma of the lung to erlotinib after gefitinib in never smoker Korean woman.
- Successful treatment of non-small cell lung cancer with gefitinib after erlotinib-induced severe eyelid erosion: Two case reports.